Discontinuation of Long-acting Injectable Cabotegravir–Rilpivirine in a Large Clinic Cohort
Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.
Authors
- Samantha E. Dilworth (ORCID: https://orcid.org/0000-0002-5451-5486)
- Matthew D. Hickey (ORCID: https://orcid.org/0000-0001-8913-1602)
- Chesa Cox (ORCID: https://orcid.org/0000-0002-5918-2668)
- Monica Gandhi (ORCID: https://orcid.org/0000-0002-7025-1994)
- Mary Shiels
- Elizabeth Imbert (ORCID: https://orcid.org/0000-0002-3060-3596)
- Ayesha Appa (ORCID: https://orcid.org/0000-0002-4602-5954)
- Janet R. Grochowski (ORCID: https://orcid.org/0000-0002-9816-7073)
- Katerina A. Christopoulos (ORCID: https://orcid.org/0000-0002-8598-2191)
- Xavier A. Erguera (ORCID: https://orcid.org/0000-0002-7632-0321)
- Jon Oskarsson
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- University of San Francisco (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1093/ofid/ofaf600
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00